×
For best experience we recommend to activate Javascript in your browser.
Recombinant IL31RA (Nemolizumab Biosimilar) antibody
The Human Monoclonal anti-IL31RA (Nemolizumab Biosimilar) antibody (ABIN7675775) specifically detects IL31RA (Nemolizumab Biosimilar) in ELISA, FACS, BLI, Func and SPR.
The antibody is reactive with Human samples.
Catalog No. ABIN7675775
$294.23
$346.15
save $51.92 (-15 %)
Plus shipping costs $50.00
1 mg ABIN7581506
100 μg ABIN7675775
1 mg ABIN7581506
100 μg ABIN7675775
Delivery in 10 to 11 Business Days
Quick Overview for Recombinant IL31RA (Nemolizumab Biosimilar) antibody (ABIN7675775)
Target
IL31RA (Nemolizumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for IL31RA (Nemolizumab Biosimilar) antibodies
Human
Clonality
All clonalities for IL31RA (Nemolizumab Biosimilar) antibodies
Monoclonal
Conjugate
All conjugates for IL31RA (Nemolizumab Biosimilar) antibodies
This IL31RA (Nemolizumab Biosimilar) antibody is un-conjugated
Application
ELISA, Flow Cytometry (FACS), Bio-Layer Interferometry (BLI), Functional Studies (Func), Surface Plasmon Resonance (SPR)
Product Details anti-IL31RA (Nemolizumab Biosimilar) Antibody
(hide)
Expression System
CHO Cells
Purpose
Anti-IL-31Ra Reference Antibody (nemolizumab)
Characteristics
Anti-IL-31Ra Reference Antibody (nemolizumab) is expressed from CHO. The heavy chain type is huIgG2, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
Purity
>95 %
Isotype
IgG2
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Lyophilized
Concentration
1 mg/mL
Buffer
25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
Storage
4 °C,-80 °C
Storage Comment
+4°C,-80°C
Target Details for IL31RA (Nemolizumab Biosimilar)
(hide)
Target
IL31RA (Nemolizumab Biosimilar)
Alternative Name
IL-31Ra (Nemolizumab Biosimilar)
Target Type
Biosimilar
Molecular Weight
145.5 kDa
UniProt
Q8NI17
Recently viewed
(hide)
Chat with us , powered by LiveChat